Dietary polyunsaturated fatty acid and antioxidant modulation of vascular dysfunction in the spontaneously hypertensive rat.
Two currently available edible oils-olive and canola-and two oil blends of plant origin having different n-3/n-6 polyunsaturated fatty acid (PUFA) ratios were evaluated for their ability to modify vascular dysfunction in the spontaneously hypertensive rat (SHR). Synthetic diets supplemented with test oils (5% w/w) were fed for 12 weeks, and segments of thoracic aorta used to assess vascular function. Vessels from the SHR displayed a spontaneous constrictor response after the inhibition of endothelial cell nitric oxide (NO) with N(omega)-nitro-L-arginine (NOLA). Dietary alpha -linoleate enrichment led to a reduction (P<0.05) in this abnormality with a dietary n-3/n-6 PUFA ratio of 1.0 (blend-1) yielding the best outcome. Relaxation to acetylcholine (ACh) was unaffected by dietary lipid supplementation. NOLA treated rings also displayed contractions to ACh that were abolished by indomethacin, thromboxane antagonists SQ29548, picotamide and flavonoids kaempferol and quercetin. In contrast, alpha-tocopherol, rutin and the lipoxygenase inhibitor esculetin resulted in only partial (30-55%) inhibition, and were ineffective against the NOLA-induced contraction suggesting the operation of different biochemical mechanisms in mediating the spontaneous and Ach-induced contractions. Results implicate plant-based oils and antioxidants as potential modulators of vascular function.
Abeywardena
M Y
MY
CSIRO, Health Sciences and Nutrition, Kintore Avenue, Adelaide, SA 5000, Australia. mahinda.abeywardena@hsn.csiro.au
Head
R J
RJ
D000109:Acetylcholine / Q000037:antagonists & inhibitors / Q000494:pharmacology; D000818:Animals; D000975:Antioxidants / Q000378:metabolism* / Q000494:pharmacology; D001011:Aorta / Q000378:metabolism; D019086:Bridged Bicyclo Compounds, Heterocyclic; D002317:Cardiovascular Agents / Q000494:pharmacology; D004032:Diet; D004305:Dose-Response Relationship, Drug; D004730:Endothelium, Vascular / Q000378:metabolism; D005231:Fatty Acids, Unsaturated / Q000378:metabolism*; D005419:Flavonoids / Q000494:pharmacology; D006834:Hydrazines / Q000494:pharmacology; D006973:Hypertension / Q000517:prevention & control*; D007213:Indomethacin / Q000494:pharmacology; D044949:Kaempferols; D050356:Lipid Metabolism; D009569:Nitric Oxide / Q000378:metabolism; D010795:Phthalic Acids / Q000494:pharmacology; D010938:Plant Oils / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D011794:Quercetin / Q000031:analogs & derivatives* / Q000494:pharmacology; D051381:Rats; D011918:Rats, Inbred SHR; D012431:Rutin / Q000494:pharmacology; D014468:Umbelliferones / Q000494:pharmacology; D024502:alpha-Tocopherol / Q000494:pharmacology
D000975:Antioxidants; D019086:Bridged Bicyclo Compounds, Heterocyclic; D002317:Cardiovascular Agents; D005231:Fatty Acids, Unsaturated; D005419:Flavonoids; D006834:Hydrazines; D044949:Kaempferols; D010795:Phthalic Acids; D010938:Plant Oils; D010975:Platelet Aggregation Inhibitors; D014468:Umbelliferones; D009569:Nitric Oxide; D012431:Rutin; C011581:picotamide; C006552:kaempferol; C045749:SQ 29548; D011794:Quercetin; D024502:alpha-Tocopherol; D000109:Acetylcholine; C007628:esculetin; D007213:Indomethacin